GOSS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
9.2M
-45.5%
17.0M
+22.9%
13.8M
+3.8%
13.3M
+15.7%
11.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
9.2M
-45.5%
17.0M
+22.9%
13.8M
+3.8%
13.3M
+15.7%
11.5M
Operating Expenses
35.3M
-42.9%
61.8M
+3.3%
59.8M
-4.1%
62.4M
+24.2%
50.3M
R&D
26.4M
-38.7%
43.1M
-12.0%
48.9M
-7.7%
53.0M
+27.5%
41.6M
SG&A
8.9M
-52.5%
18.7M
+71.9%
10.9M
+16.1%
9.4M
+8.2%
8.7M
Operating Income
-26074000
+41.9%
-44866000
+2.5%
-46039000
+6.3%
-49114000
-26.7%
-38765000
EBITDA
-26070000
+41.9%
-44861000
+14.3%
-52333000
-6.6%
-49108000
-26.7%
-38759000
Net Income
16.9M
+136.2%
-46664000
+1.2%
-47238000
+2.0%
-48221000
-26.0%
-38273000
EPS (Basic)
$0.05
+125.0%
$-0.20
+0.0%
$-0.20
+4.8%
$-0.21
-23.5%
$-0.17
EPS (Diluted)
$-0.08
+60.0%
$-0.20
+0.0%
$-0.20
+4.8%
$-0.21
-23.5%
$-0.17
Shares (Diluted)
328.8M
+40.4%
234.1M
+0.9%
232.0M
+1.8%
228.0M
+0.3%
227.3M
Gossamer Bio (GOSS) โ€” Financials